Pricing Log in Create free account
Friday 6 November 2026 Export GTBP’s income statement to Excel — free account

GT Biopharma, Inc.

GTBP Healthcare Biotechnology

EPS
+98.9%
Free cash flow
−41.3%

Quarter to June 2026, against a year earlier

4.42 0.12 −2.64%
Market cap
$9.4M
P/E
0.8×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−5138.41
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 9.36
Revenue ttm 0.06
Net income ttm (4.76)
Free cash flow ttm (14.43)
Net debt Q (5.05)
Valuation
P/E 0.76
Forward P/E —
Price / sales 114.39 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.92
Financial health
Current ratio Q 2.61 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (70.50)
Growth
Revenue growth Q −100.00% (below 0%: shrinking)
Operating income growth Q −198.22% (below 0%: shrinking)
EPS, this year +93.56% (at or above 15%: strong)
EPS, next year A +25.58% (at or above 15%: strong)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A +65.26% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 475×, against a ten-year median of 505×; over the ten years it ranged from 166× in 2016 to 23,094,733× in 2016.
P/S against its own 10 years 22.42%
10-year low 10-year high
P/B against its own 10 years 56.50%
10-year low 10-year high
EV/Sales against its own 10 years 45.60%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 14 4 7 5
Receivables — — — —
Inventory — — — —
Other — — 1 1
14 4 8 6
2023 2024 2025 Q'26
Payables 4 4 1 1
ST’ Debt — — — —
Other 1 0 0 —
7 6 2 2

Compound Annual Growth %

10y 5y 3y
Sales — 19.67% (57.10%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% (20.99%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −2.00 Actual −3.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −9.50 −20.75 Miss by 11.25
Q4 FY25 −5.50 −0.50 Beat by 5.00
Q1 FY26 −2.00 −2.75 Miss by 0.75
Q2 FY26 −2.00 −3.00 Miss by 1.00
Q3 FY26 −2.50 — Reports 13 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (2.75) (3.00) — — —
’25 (8.25) (272.09) 25.99 (14.46) (167.00)
’24 (41.00) (54.25) (38.25) (41.50) (173.50)
’23 (5.24) (37.54) (45.04) (54.28) (141.00)
’22 (127.63) (75.07) (165.16) (135.13) (495.50)
’21 (1.37k) (112.61) (127.63) (390.39) (1.55k)
’20 (255.36) (3.09k) (510.71) (962.29) (4.84k)
Fiscal quarters ending in the months shown.

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (4) — — —
’25 (2) (3) (4) (4) (13)
’24 (4) (4) (3) (2) (13)
’23 (3) (2) (2) (2) (9)
’22 (5) (3) (3) (4) (15)
’21 (4) (4) (4) (4) (16)
’20 0 (3) (2) (2) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (4) — — —
’25 (2) (3) (4) (4) (13)
’24 (4) (4) (3) (2) (13)
’23 (3) (2) (2) (2) (9)
’22 (5) (3) (3) (4) (15)
’21 (4) (4) (4) (4) (16)
’20 0 (3) (2) (2) (7)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — 0 — — — — —
Gross margin, % 0.00 0.00 0.00 0.00 — — — — — — 41.67 0.0 pt
EBT 10 (144) (259) (39) (28) (58) (21) (8) (13) (28) (5) n/m
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
Net income 10 (144) (259) (39) (28) (58) (21) (8) (13) (28) (5) n/m
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings 3,327,385.00 (109,037.60) (65,882.20) (8,554.47) (4,842.34) (1,546.55) (495.50) (141.00) (173.50) (167.00) 5.78 n/m
Cash flow 0.00 (4,176.92) (2,737.69) (813.11) (1,252.07) (416.16) (358.05) (164.23) (170.01) (58.57) (9.29) n/m
Capex 0.00 (3.08) (9.23) 44.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow 0.00 (4,180.00) (2,746.92) (768.67) (1,252.07) (416.16) (358.05) (164.23) (170.01) (58.57) (9.29) n/m
Book value 0.00 193,606.92 2,915.38 (4,291.11) (5,074.66) 584.27 276.09 138.70 (22.00) 26.24 2.30 n/m
Shares, m 0 0 0 0 0 0 0 0 0 0 1 n/m
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow (2) (5) (11) (4) (7) (16) (15) (9) (13) (13) (14) +23.5%
Capex — 0 0 0 — — — — — — 0 n/m
Free cash flow (2) (5) (11) (3) (7) (16) (15) (9) (13) (13) (14) +23.5%
Balance, $m
Balance, $m Working capital (19) (2) (14) (19) (29) 22 12 7 (2) 6 4 n/m
Net debt 11 (1) 11 13 21 (32) (17) (14) (4) (7) (5) n/m
Shareholders’ equity (19) 252 11 (19) (29) 22 12 7 (2) 6 4 n/m
Returns, %
Returns, % ROA 24,729.11 (113.35) (185.29) (299.65) (934.32) (306.70) (85.41) (49.26) (143.53) (558.42) (176.27) (25,287.5) pt
ROIC 0.00 (33.74) (710.97) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (28.11) (123.88) (197.06) 972.88 116.09 1,541.48 (124.15) (79.10) (453.55) (1,674.31) 102.03 (1,646.2) pt
People
People Employees 2 5 3 2 3 8 2 2 1 1 — (7.4%)
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2015 · latest quarter Dec 2015 · fundamentals updated 26 Oct 2026

GT Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AZR Azora Therapeutics, Inc. $9.7M — (loss-making) — — n/m −263.66% (below 0%: shrinking) 0.00% 0.00% Compare
GTBP GT Biopharma, Inc. $9.4M 0.8× — −100.00% (below 0%: shrinking) n/m −41.34% (below 0%: shrinking) 0.00% 0.00%
AEON AEON Biopharma, Inc. $9.4M — (loss-making) — — n/m −76.85% (below 0%: shrinking) — 0.00% Compare
PHIO Phio Pharmaceuticals Corp. $9.3M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −58.67% (below 0%: shrinking) 0.00% 0.00% Compare
MBRX Moleculin Biotech, Inc. $9.2M 0.0× — — n/m −19.26% (below 0%: shrinking) 0.00% 0.00% Compare
CURX Curanex Pharmaceuticals Inc $9.1M — (loss-making) — — n/m −272.32% (below 0%: shrinking) — 0.00% Compare
CMMB Chemomab Therapeutics Ltd. Sponsored ADR $9.1M — (loss-making) — — n/m +47.89% (above 0%: growing) 0.00% 0.00% Compare
CALC CalciMedica Inc. $8.9M — (loss-making) — — n/m +31.42% (above 0%: growing) 0.00% 0.00% Compare
BLRX BioLineRx Ltd. $8.8M — (loss-making) — (loss-making) −3.29% (below 0%: shrinking) n/m −1,827.71% (below 0%: shrinking) 79.93% (1,215.31%) Compare
Median of peers $9.1M — — — — −67.76% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 13 October 2026

Ownership

Directors and executive officers, together 1.11%
Bristol Investment Fund, Ltd 9.99%
Five Narrow Lane, L.P. 9.99%
Robert A. Marzilli 9.99%
Rainforest Partners LLC 9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

GT Biopharma, Inc. (GTBP) Latest News

26 Oct

Impact 3 · · GlobeNewswire

16 Sep

Impact 4 ·

15 Sep

Impact 4 ·
Impact 3 ·

1 Jun

Impact 4 · · Benzinga
Impact 3 · · GlobeNewswire

15 May

Impact 3 · · GlobeNewswire
Impact 3 · · GlobeNewswire

14 May

Impact 4 · · GlobeNewswire
Impact 4 · · Benzinga
Impact 3 · · GlobeNewswire

16 Mar

Impact 4 · · Zacks

2 Mar

Impact 3 · · GlobeNewswireMobyMobyZacksGuruFocus.comMarketBeatGuruFocus.com

3 Feb

Impact 4 · · GlobeNewswire

15 Jan

Impact 4 · · GlobeNewswire

8 Dec

Impact 4 · · TheStreet

19 Nov

Impact 4 · · ACCESS NewswireGuruFocus.comMotley FoolSimply Wall St.GuruFocus.comSimply Wall St.GuruFocus.comSimply Wall St.

14 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswireGuruFocus.comGuruFocus.com

23 Oct

Impact 4 · · GlobeNewswire

8 Oct

Impact 4 ·
Impact 4 ·

6 Oct

Impact 3 ·

14 Aug

Impact 3 · · GlobeNewswire

11 Aug

Impact 4 ·

13 Jun

Impact 3 · · GlobeNewswire

19 May

Impact 4 ·

4 Mar

Impact 3 ·

25 Feb

Impact 3 · · GlobeNewswire

27 Jan

Impact 4 · · GlobeNewswire
stockrow.com/GTBP · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com